enVVeno raises $28M in PIPE financing with milestone-based warrants

enVVeno Medical Corp

Gross proceeds of $28M from sale of 3,844,704 shares, pre-funded warrants for 977,900 shares, and two tranches of warrants.
Tranche A warrants (4,822,604 shares) at $6.945, expire 30 days post SAVVE top-line data or Oct 2024.
Tranche B warrants (4,822,604 shares) at $8.334, expire 30 days post FDA PMA for VenoValve or Oct 2026.
Net proceeds ~$25.9M; funds for VenoValve and enVVe development and working capital.
Ladenburg Thalmann placement agent; 7% cash fee and warrants for 241,130 shares at $6.945.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

enVVeno Medical Corp entered into Registration Rights Agreement with certain institutional investors (effective 2023-10-06).

Action: entry
Counterparty: certain institutional investors
Effective: 2023-10-06

Exact text from the filing

In connection with the offering, the Company and the Investors entered into a Registration Rights Agreement dated October 6, 2023 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares and Warrant Shares.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

enVVeno Medical Corp entered into Securities Purchase Agreement with certain institutional investors valued at approximately $28 million (effective 2023-10-06).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $28 million
Effective: 2023-10-06

Exact text from the filing

On October 6, 2023, enVVeno Medical Corporation (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) for the purpose of raising approximately $28 million in gross proceeds for the Company.

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

enVVeno Medical Corp filing history →

Source: SEC EDGAR

accession 0001493152-23-037065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.